FindTrial
Sign In

A long term study of SPP100 in patients with essential hypertension

A long term study of SPP100 in patients with essential hypertension

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220180
Enrollment
300
Registered
2005-11-25
Start date
2005-11-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

investigational material(s) Generic name etc : SPP100 INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational material : Oral

Sponsors

Novartis Pharma K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion Criteria - Male or female aged 20 to 80 years old - Diagnosed as essential hypertension Exclusion Criteria - Patients with secondary hypertension or suspected of having secondary hypertension. - Patients suspected of having malignant hypertension - Patients with any serious diseases or symptoms Other protocol-defined inclusion/exclusion criteria also apply

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Primary Outcomes: Incidence of adverse events, vital signs, abnormal laboratory changes,etc. Secondary Outcomes: Change from baseline in diastolic blood pressure after 52 weeks; Change from baseline in systolic blood pressure after 52 weeks; Diastolic blood pressure 10 mmHg after 52 weeks—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026